GlassScriptPhysician profile
Lorie Beth Natoli
NPI 1215943436
$3,762.26
in general payments reported to CMS, 2019-2025
31 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.58 · 2022: $229 · 2023: $285 · 2024: $1,490 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,415 · Education: $40.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.06 |
| Education | $40.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $937.80 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $392.04 | 2023-2025 | Dupixent |
| Pfizer INC. | $323.06 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.62 | 2021-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $284.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $218.23 | 2023-2025 | |
| Davol INC. | $147.09 | 2024 | Arista Ah Flexitip |
| Aimmune Therapeutics, INC. | $141.54 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $141.08 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $111.79 | 2024-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $80.15 | 2024-2025 | Omvoh |
| Organon LLC | $61.58 | 2025 | Renflexis, Hadlima, Nexplanon |
| Ardelyx, INC. | $60.83 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $58.58 | 2025 | Iqirvo |
| Novo Nordisk INC | $51.67 | 2025 | Wegovy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $41.15 | 2022-2025 | Tremfya |
| Celltrion USA INC. | $40.88 | 2023 | Yuflyma |
| Merck Sharp & Dohme LLC | $39.32 | 2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.78 | 2024 | Cyltezo |
| Shield Therapeutics INC | $35.24 | 2023-2025 | Accrufer |
| Intercept Pharmaceuticals, INC. | $34.45 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $27.50 | 2025 | Exparel |
| Ironwood Pharmaceuticals, INC | $27.15 | 2023 | Linzess |
| Teva Pharmaceuticals USA, INC. | $22.92 | 2025 | |
| Digestive Care, INC. | $22.38 | 2025 | Pertzye |
| Sandoz INC. | $21.77 | 2024 | Hyrimoz |
| Pharmacosmos Therapeutics INC. | $20.61 | 2023 | Monoferric |
| Nestle Healthcare Nutrition INC. | $19.28 | 2023 | |
| Ferring Pharmaceuticals INC. | $17.12 | 2024 | Rebyota |
| Exact Sciences Corporation | $16.81 | 2025 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $16.35 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorie Natoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.